These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial. Braly PS; Berek JS; Blessing JA; Homesley HD; Averette H Gynecol Oncol; 1995 Feb; 56(2):164-8. PubMed ID: 7896179 [TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look. Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026 [TBL] [Abstract][Full Text] [Related]
8. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Covens A; Blessing J; Bender D; Mannel R; Morgan M; Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022 [TBL] [Abstract][Full Text] [Related]
9. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer. Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134 [TBL] [Abstract][Full Text] [Related]
10. Relationship between peritoneal washing cytology through implantable port system (IPS-cytology) and second-look laparotomy in ovarian cancer patients with unmeasurable residual diseases. Fujiwara K; Yamauchi H; Yoshida T; Suzuki S; Oda T; Kohno I Gynecol Oncol; 1998 Aug; 70(2):231-5. PubMed ID: 9740696 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Pretorius RG; Hacker NF; Berek JS; Ford LC; Hoeschele JD; Butler TA; Lagasse LD Cancer Treat Rep; 1983 Dec; 67(12):1085-92. PubMed ID: 6228294 [TBL] [Abstract][Full Text] [Related]
12. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study. Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240 [TBL] [Abstract][Full Text] [Related]
13. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer. Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221 [TBL] [Abstract][Full Text] [Related]
15. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related]
16. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up. Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354 [TBL] [Abstract][Full Text] [Related]
17. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Markman M; Reichman B; Hakes T; Rubin S; Lewis JL; Jones W; Barakat R; Curtin J; Almadrones L; Hoskins W Gynecol Oncol; 1993 Jul; 50(1):100-4. PubMed ID: 8349150 [TBL] [Abstract][Full Text] [Related]